The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cholesterol Levels in Patients with RA Starting Methotrexate

Cholesterol Levels in Patients with RA Starting Methotrexate

February 25, 2016 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although research regarding the increased cardiovascular (CV) morbidity and mortality in rheumatoid arthritis (RA) has burgeoned in recent years, the need remains for a better understanding of the effects of widely used DMARDs on CV risk and risk factors in RA patients. These authors set out to evaluate the long-term changes in cholesterol levels in patients with early RA who were randomized to begin treatment with methotrexate (MTX) monotherapy, MTX plus etanercept, or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.

You Might Also Like
  • Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia

They describe the long-term effects of disease activity, DMARD use and patient characteristics on cholesterol levels in a large clinical trial of patients with early RA, demonstrating two major points: 1) suppression of RA-related inflammation is associated with increases in cholesterol levels, which are highest in the early phase of therapy regardless of treatment, and 2) use of triple therapy is associated with decreases in the total cholesterol:high-density lipoprotein (HDL) cholesterol ratio over long-term follow-up. The effects of these cholesterol changes on CV events in patients with RA warrant further study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: Levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and HDL cholesterol were analyzed in 416 patients participating in the TEAR trial during 102 weeks of follow-up. Associations of cholesterol changes with disease activity and drug treatment were evaluated using repeated-measures analysis with mixed-effect linear models to model within-subject covariance over time.

Results: Mixed-effect models controlling for traditional CV risk factors, TEAR treatment, and baseline prednisone and statin use demonstrated significant inverse associations of RA disease activity with changes in cholesterol over time. Decreases in the 28-joint Disease Activity Score, the C-reactive protein level or the erythrocyte sedimentation rate were associated with increases in levels of HDL cholesterol, LDL cholesterol and total cholesterol in all treatment groups (P<0.001–0.035). Triple therapy was strongly associated with higher levels of HDL cholesterol, lower levels of LDL cholesterol and higher ratios of total cholesterol:HDL cholesterol (P<0.001 for all) compared with MTX monotherapy or MTX plus etanercept therapy over the two-year follow-up.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Conclusion: Decreases in RA disease activity over long-term follow-up were associated with increases in cholesterol levels in patients with early RA treated with either biologic or nonbiologic therapies. The use of triple therapy during two years of follow-up was associated with higher HDL cholesterol levels, lower LDL cholesterol levels and lower total cholesterol:HDL cholesterol ratios compared with those observed in patients who received MTX monotherapy or MTX plus etanercept combination therapy. Additional studies are needed to assess the effects of these cholesterol changes on CV events in patients with RA.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, cholesterol, Methotrexate, Rheumatiod arthritis, triple therapy

You Might Also Like:
  • Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia
  • Patients with RA Who Respond to Treatment Experience Increased Cholesterol

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)